COVID-19 and hypertension.

Abstract

Infection with SARS-Cov-2 is the causative agent of coronavirus disease 2019 (COVID-19), which the WHO has described as a pandemic. As of July 27th, 2020, this disease has killed more than 16.3 million people worldwide and it appears that underlying cardiovascular disease constitutes substantial comorbidity correlated with the clinical decline and adverse outcomes in COVID-19 patients. Preliminary reports stated that hypertension may be associated with increased risk of SARS-Cov-2 infection but it now appears that older age and hypertension-related comorbidities somewhat confound this relationship. However, following the initial findings of using RAAS blockers with a higher risk of SARS-Cov-2 infection and a more serious course of COVID-19, it is now recognized that no solid scientific results are available in humans to support them. The application of RAAS blockers care in patients with appropriate indications are widely recommended by major international research organizations.